Changes in serum lipid profiles caused by three regimens of interferon‐free direct‐acting antivirals for patients infected with hepatitis C virus

Takako Inoue(Kaneka (United States)), Yasuhito Tanaka(Kumamoto University), Kei Fujiwara(Nagoya City University), Noboru Shinkai(Nagoya City University), Etsuko Iio(Nagoya City University), Shunsuke Nojiri(Nagoya City University), Takaaki Goto(Nagoya City University Hospital), Takeshi Matsui(Nagoya City University), Kentaro Matsuura(Nagoya City University), Kayoko Matsunami(Nagoya City University)
Hepatology Research
August 19, 2017
10.1111/hepr.12970
Cited by 41

Related Papers

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Cyclosporin A and Its Analogs Inhibit Hepatitis B Virus Entry Into Cultured Hepatocytes Through Targeting a Membrane Transporter, Sodium Taurocholate Cotransporting Polypeptide (NTCP)
|Hepatology|2013|259
Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization
|Proceedings of the National Academy of Sciences|2019|241
Gut Dysbiosis Associated With Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|187
Interleukin-1 and Tumor Necrosis Factor-α Trigger Restriction of Hepatitis B Virus Infection via a Cytidine Deaminase Activation-induced Cytidine Deaminase (AID)
|Journal of Biological Chemistry|2013|166